You are now leaving Abacavir HSR Support. ViiV/GSK do not recommend, endorse or accept liability for sites controlled by third parties.
The role of HLA-B*5701
Pharmacogenetic risk factor for abacavir HSR
The HLA-B*5701 allele is more common among patients who have a suspected hypersensitivity reaction to abacavir compared with those who do not, regardless of race.
No other pharmacogenetic markers have been found that identify patients at risk of abacavir hypersensitivity.
Prospective pharmacogenetic screening for HLA-B*5701 can be used to identify patients at high risk for abacavir hypersensitivity.
However, HLA-B*5701 is not always present in people who have a suspected abacavir HSR. Therefore, clinical diagnosis of suspected HSR to abacavir remains the basis of clinical decision making.
HLA-B*5701 screening for risk of abacavir HSR should never be substituted for appropriate clinical vigilance and patient management in individuals receiving abacavir.